Connect With RxStrategies at the 2019 Community Health Institute & Expo
RxStrategies’ Rhodie Smith and Todd Hudnall will be at the 2019 Community Health Institute & Expo in Chicago, IL, August 18 – 20. The NACHC Community Health Institute (CHI) and EXPO is the largest annual gathering of health professionals in the area. This conference takes place in a time to where according to the…
Meet RxStrategies in Philadelphia for 340B Summit
Jonathan Ghenn and Rhodie Smith will be attending and meeting with industry leaders during the 4th Annual Covered Entities 340B Summit hosted by World Congress, May 16 – 17 in Philadelphia, PA. RxStrategies is proud to be a Supporting Sponsor for the Summit. This event brings HRSA grantees and covered entities together to discuss the…
Simplify 340B with Dashboard Analytics
Our powerful analytics platform provides users with robust and insightful visibility into their 340B program. With an intuitive, cloud-based platform, an advanced reporting machine, and reliable analytics, RxStrategies’ Dashboard Analytics solution simplifies your entire 340B program. Real-time accumulator views, WAC-spend analyses, robust drill-down capabilities, and custom report creations provide our users access to the exact…
The Future of Policy at NACHC 2019
March 27 – 30, RxStrategies representatives Rhodie Smith and Justin Rolling will attend the 2019 Policy and Issues Forum hosted by the National Association of Community Health Centers (NACHC). As one of the largest conferences on health policy, people from all corners of the administration and operations of health care will attend. The priorities…
Clinical Insights: November 7, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with…
Clinical Insights: May 9, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Plenvu® (polyethylene glycol 3350 with electrolytes) – May 7, 2018 – Salix Pharmaceuticals, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Plenvu®…
Clinical Insights: April 3, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval SymfiTM (efavirenz, lamivudine and tenofovir disoproxil fumarate) – March 22, 2018 – Mylan N.V. announced that it will introduce in the U.S. a third cost-saving HIV…
Clinical Insights: March 23, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval IlumyaTM (tildrakizumab-asmn) – New Drug Approval – March 21, 2018 – Sun Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved…
Clinical Insights: October 10, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Zilretta™ (triamcinolone acetonide extended-release) – October 6, 2017 – Flexion Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Zilretta™ (triamcinolone acetonide extended-release…
Clinical Insights: September 15, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Aliqopa™ (copanlisib) – September 14, 2017 – The U.S. Food and Drug Administration granted accelerated approval to Aliqopa™ (copanlisib) for the treatment of adults with relapsed…
Clinical Insights: August 18, 2017
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Besponsa® (inotuzumab ozogamicin) – August 17, 2017 – The U.S. Food and Drug Administration approved Besponsa® (inotuzumab ozogamicin) for the treatment of adults with relapsed or…